Literature DB >> 6088759

Effects of the highly selective kappa opioid, U-50, 488, on renal function in the anesthetized dog.

G R Slizgi, C J Taylor, J H Ludens.   

Abstract

Intravenous administration of U-50,488 (a chemically novel and highly selective kappa agonist) resulted in dose-dependent increases in urine formation in anesthetized dogs. The increase in urine formation was not accompanied by an increase in sodium or potassium excretion; thus, U-50,488 behaved like a water diuretic. In addition, a dose-dependent fall in blood pressure was noted after U-50,488 administration. Despite the effect on blood pressure, no changes in renal plasma flow (p-aminohippurate clearance) or glomerular filtration rate (inulin clearance) were detected at any dose tested. Apparently, the diuresis was primarily due to tubular effects and not to changes in renal hemodynamics. Intravenous infusion of antidiuretic hormone (2 pmol/min/kg) abolished completely the diuretic response to U-50,488 (5 mg/kg). This implied that the diuresis was mediated by an effect of the drug on antidiuretic hormone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088759

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Kappa-opioid-receptor agonists modulate the renal excretion of water and electrolytes in anaesthetized rats.

Authors:  N Ashton; R J Balment; T P Blackburn
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

2.  Kappa-opioid-induced changes in renal water and electrolyte management and endocrine secretion.

Authors:  N Ashton; R J Balment; T P Blackburn
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

3.  Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man.

Authors:  H J Kramer; W Uhl; B Ladstetter; A Bäcker
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

4.  Mechanism of diuretic action of spiradoline (U-62066E)--a kappa opioid receptor agonist in the human.

Authors:  G H Rimoy; N K Bhaskar; D M Wright; P C Rubin
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

5.  A series of novel, highly potent and selective agonists for the kappa-opioid receptor.

Authors:  A G Hayes; P J Birch; N J Hayward; M J Sheehan; H Rogers; M B Tyers; D B Judd; D I Scopes; A Naylor
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

6.  Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors?

Authors:  Caroline M Kopruszinski; Robson Vizin; Moe Watanabe; Ashley L Martinez; Luiz Henrique Moreira de Souza; David W Dodick; Frank Porreca; Edita Navratilova
Journal:  J Headache Pain       Date:  2022-09-30       Impact factor: 8.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.